Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Cerebrovascular Diseases · doi:10.1159/000087203 · Cited by 410
RetractedWimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Manabe, S., Kuno, H., & Oizumi, K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.1.64 · Cited by 131
Retracted(2007) · Neurology · doi:10.1212/01.wnl.0000257089.50476.92 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetracted(2003) · Neurology · doi:10.1212/01.wnl.0000078892.24356.90 · Cited by 51
RetractedSato, Y., Kuno, H., Kaji, M., Saruwatari, N., & Oizumi, K. (1999) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199909000-00008 · Cited by 37
RetractedAnti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials
Zhong, Z., & Chen, J. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00007 · Cited by 30 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI · Paper page
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
Items 601–700 of 741
Comparative Effectiveness Study of Osteoporosis Medications Using Electronic Medical Records
Lyu, H. (2019) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
WITHDRAWN: Understanding Osteoporosis Screening Practices in Men: A Nationwide Physician Survey
Choksi, P. U., Gay, B. L., Reyes‐Gastelum, D., Haymart, M. R., & Papaleontiou, M. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.05.002
RetractedTastad, C. A. (2020) · Purdue e-Pubs (Purdue University System) · doi:10.25394/pgs.13252682
Reframing: A Grounded Theory Study of Postmenopausal Women Following Osteoporotic Fracture
Barber, A. D. (2021) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.8081
A call for research on soft tissue manipulation (STM) as a bone anabolic therapy
Anloague, A., Patel, D., Henderson, S., Rolfs, H., Powell, M., Patel, S. B., Marshall, V. R., Wacker, B. G., LaFave, N. M., Young, C. M., et al. (2021) · Journal of Rehabilitation Therapy · doi:10.29245/2767-5122/2021/1.1125
Fu, S., Wang, C., & Li, C. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13401
Some allometric patterns of radiation diagnostics of the upper limb
Minasov, T. B., Yakupova, E. R., Khairutdinov, R. F., Imaeva, A. K., & Glazunov, S. Y. (2021) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2112-03
Reeve, K., Meola, A., & West, R. (2022) · Springer eBooks · doi:10.1007/978-3-030-54441-6_129
New Horizons for Hydroxyapatite Supported by DXA Assessment—A Preliminary Study
Litak, J., Grochowski, C., Rysak, A., Mazurek, M., Blicharski, T., Kamieniak, P., Wolszczak, P., Rahnama, M., & Litak, G. (2022) · Materials · doi:10.3390/ma15030942
Elbüken, G., Ağgül, H., Bilen, O., & Zuhur, S. S. (2022) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.1032870
Protective Effect of Lepidium Sativum Seeds and Buttermilk on Osteoporosis in Female Rats
مراد, ر. م., المجيد, س. س. ع., حنا, ا. ت., & حسن, د. ر. (2022) · المجلة العلمية للتربية النوعية والعلوم التطبيقية · doi:10.21608/sjseas.2022.221947
UNDERSTANDING OSTEOPOROSIS, IT'S RISK, PREVENTION AND TREATMENT
Gayatri, S. P. P. (2022) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.6527728
Reeve, K., Meola, A., & West, R. (2020) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_129-2
(2018) · Andrology · doi:10.1111/andr.12539
(2020) · Springer Publishing Company eBooks · doi:10.1891/9780826173270.ap08
Stanoyevitch, A., Zhang, L., Sanz, J., Follett, R. W., & Bell, D. S. (2020) · doi:10.21203/rs.2.17503/v2
“Seventy-one percent of osteoporotic fractures occur in women, while breast cancer is the most common tumor all over the world [1-3].”
Background刘, 宝. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125552
Zhang, C., Song, D., Zhang, L., Liu, L., & Zhu, B. (2022) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2022.3312
Osteosarcopenia and Fragility Fracture: A Community Perspective
Li, L. W., Ho, W. T., & Lau, S. Y. (2022) · Quality of life in Asia · doi:10.1007/978-981-19-3061-4_18
Denosumab for preventing fractures in postmenopausal women with osteoporosis
Yanai, R., Okabayashi, S., Luo, Y., Fujii, K., Miyawaki, Y., Yajima, N., & Watanabe, N. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014680
Reis, T. G. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.87.2021.tde-24112022-121110
Pietrzyk, B. Z. (2022) · Austin Journal of Orthopedics & Rheumatology · doi:10.26420/austinjorthopaderheumatol.2022.1112
Александрович, И. Н., Zguralskaya, E. N., & Владимировна, М. М. (2023) · INFORMACIONNYE TEHNOLOGII · doi:10.17587/it.29.104-112
Jin, M., Cao, R., Niu, X., & Shan, P. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01237-7
“Subjects aged 50 years with BMD lower than 2.0 SD of the BMD for the same age and sex ( Z -score ≤2.0) were diagnosed with osteopenia [14, 15].”
InfluentialPart I: Interactive case: Menopause
Cieri‐Hutcherson, N. E., & Vernon, V. P. (2023) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1814
Diagnostic Value of Trabecular Bone Score in Osteoporosis
Rajaei, A., Mohammadi, K., Oroei, M., & Farsad, F. (2023) · Iranian Journal of Radiology · doi:10.5812/iranjradiol-131845
Freeman, S., & Mujahid, N. (2023) · Journal of Hospital Medicine · doi:10.1002/jhm.13181
Bedimo, R. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197679098.003.0041
TERAPIA DE REPOSIÇÃO HORMONAL NA MENOPAUSA: ABORDAGENS ATUAIS E CONSIDERAÇÕES DE SEGURANÇA
Lima, L. B., Santos, J. S., Júnior, P. R. H., Hernandes, N. N. F., & Ferreira, C. V. (2023) · doi:10.22533/at.ed.6242318109
AVANÇOS NEUROCIRÚRGICOS NO TRATAMENTO DA DOENÇA DE PARKINSON: UMA REVISÃO DA LITERATURA
Silva, A. M. D. S., Francisquine, M. E. D., Gomes, T. V., Júnior, P. R. H., Hernandes, N. N. F., Ferreira, R. D., Ambrosio, R. D., & Júnior, H. S. D. F. (2023) · doi:10.22533/at.ed.62423181010
A pesquisa em saúde: desafios atuais e perspectivas futuras 4
Cavalcanti, S. A. U. (2023) · doi:10.22533/at.ed.624231810
de Queiroz, A. B. L. M., Avelino, Á. I. D. S., Almeida, B. K. C., Filho, É. M. D. C., Costa, K. R., Campelo, L. M., Alencar, L. A., Lima, R. M., & da Silva, F. R. (2023) · doi:10.22533/at.ed.6242318103
ANÁLISE DOS MARCADORES DE ESTRESSE OXIDATIVO EM CORREDORES
Carvalho, N. D., de Oliveira, L. F. N., Nóbrega, E. C. M., da Silva, A. K. F., & Loureiro, A. C. C. (2023) · doi:10.22533/at.ed.62423181021
AGONISTAS DE GNRH EM MULHERES IDOSAS: A PONTE OCULTA ENTRE TERAPIA HORMONAL E OSTEOPOROSE
Canella, J. D. S., Ávila, B. D. S., Júnior, P. R. H., Hernandes, N. N. F., Ferreira, R. D., & Júnior, H. S. D. F. (2023) · doi:10.22533/at.ed.6242318108
Pimentel, L. G. D., Carvalheira, G. M., Cezar, G. F. D. G., de Abreu, F. P. R., Barbosa, V. M., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., Bastos, R. M., & Côrtes, P. P. D. R. (2023) · doi:10.22533/at.ed.62423181019
EDUCAÇÃO EM SAÚDE E GRUPOS DE CONVIVÊNCIA DE PESSOAS IDOSAS: DIÁLOGOS POSSÍVEIS
dos Santos, R. G., Fioreze, C., & Barelli, C. (2023) · doi:10.22533/at.ed.6242318107
Fernandes, F., de Oliveira, M. L., Casarin, F., VASQUES, B. S., Munhoz, O. L., & Ilha, S. (2023) · doi:10.22533/at.ed.62423181013
Ferreira, M. A. R., Mangiarini, C. B., Ibraim, M. F., Silva, G. A. L., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., Bastos, R. M., & Côrtes, P. P. D. R. (2023) · doi:10.22533/at.ed.6242318106
REDEFININDO O FUTURO: INOVAÇÕES EM PRÓTESES ORTOPÉDICAS PARA OSTEONECROSE DA CABEÇA DO FÊMUR
Henriques, L. C. M., Júnior, P. R. H., Hernandes, N. N. F., & Júnior, H. S. D. F. (2023) · doi:10.22533/at.ed.62423181015
ATENÇÃO À QUEDA DE IDOSOS NA SAÚDE PÚBLICA
Pereira, E. M., de Morais, J. A., Batista, D. N., de Oliveira, M. V. D., dos Santos, E. N., Alcântara, A. L. G., Santana, E. C., de Oliveira, J. R. G., da Silva, C. M. O., Leite, J. C. P., et al. (2023) · doi:10.22533/at.ed.6242318101
SARCOPENIA NA ERA MODERNA: DESVENDANDO NOVOS HORIZONTES NO MANEJO DO IDOSO SARCOPÊNICO
dos Santos, C. C., Júnior, P. R. H., Hernandes, N. N. F., & Júnior, H. S. D. F. (2023) · doi:10.22533/at.ed.62423181012
Ramalho, D., Rocha, G. M., & Oliveira, M. J. (2023) · Aktuelle Rheumatologie · doi:10.1055/a-2158-0872
An Introduction to Osteoporosis with a Diagnostic Approach
Pazhouhi, M., & Pazhouhi, P. (2023) · HAL
OPTIC NERVE DYSFUNCTION CAUSED BY ZOLEDRONATE: A RARE CASE REPORT
Bindu., G., Nath, S. S., & Roopa., B. (2024) · PARIPEX-INDIAN JOURNAL OF RESEARCH · doi:10.36106/paripex/5000102
Hamoda, N. Z., El-Tokhy, H. M., Mohamed, E. F., & Mohammed, D. S. (2020) · The Scientific Journal of Al-Azhar Medical Faculty Girls · doi:10.4103/sjamf.sjamf_52_20
Chronic kidney disease and osteoporosis: a two-sample Mendelian randomization studyPreprint
An, J., Shi, J.-X., Liu, X., Jiao, Y., Jing-wei, T., Yang, Y., Lu, H., & Zhuo, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4107176/v1
Wang, Z., Wang, H., Zhuang, C., Chen, W., Hoang, T.-M., Li, J., & Lin, H. R. (2023) · Figshare · doi:10.6084/m9.figshare.22792886
Zhu, B., Hu, S., Guo, J., Dong, Z., Dong, Y., & Li, F. (2023) · Figshare · doi:10.6084/m9.figshare.23258782
Zhu, B., Hu, S., Guo, J., Dong, Z., Dong, Y., & Li, F. (2023) · Figshare · doi:10.6084/m9.figshare.23258776
Zhu, B., Hu, S., Guo, J., Dong, Z., Dong, Y., & Li, F. (2023) · Figshare · doi:10.6084/m9.figshare.23258785
Zhu, B., Hu, S., Guo, J., Dong, Z., Dong, Y., & Li, F. (2023) · Figshare · doi:10.6084/m9.figshare.23258788
Bioinformatics analysis reveals the key factors affecting the progress of osteoporosis
Huang, H., Tang, W., & Yang, C. (2024) · International Journal of Public Health and Medical Research · doi:10.62051/ijphmr.v1n1.12
Al-Halbouni, W. W., Al-Tabakha, M. M., Ashames, A., Arida, A. I., & Alomar, M. J. (2022) · The Thai Journal of Pharmaceutical Sciences · doi:10.56808/3027-7922.1001
Mao, J., Lei, H., Xu, P., Liu, S., Zhou, J., Mei, M., Wang, N., & Zhang, X. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118836
Silent bone epidemic - osteoporosis
Moga, T. D., Costas, L. M., Rahota, D., Todor, L., Todor, P. C., & Moga, I. (2021) · Medicine in Evolution · doi:10.70921/medev.v27i3.1118
An, J., He, Q., Shi, J.-X., Liu, X., Jiao, Y., Jing-wei, T., Yang, Y., Lu, H., & Zhuo, L. (2025) · Research Square · doi:10.21203/rs.3.rs-5825139/v1
Zhao, J., Li, Y., Mao, Z., Wang, C., Hou, J., Li, Z., Wang, J., Tian, Y., & Li, L. (2025) · Environmental Science Processes & Impacts · doi:10.1039/d4em00815d
A novel dominant negative variant of ALPL induces hypophosphatasia
Chen, G., Liao, Q., Xing, T., Zhang, X., Ma, H., Cao, Y., Cheng, Q., Qin, A., & Ma, P. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf135
“However, the genotype–phenotype correlation was poorly understood in HPP. Numerous genetic and molecular factors are involved in the severity and broad presentation of HPP, including heterogeneity of ALPL alleles and different compound heterozygous genotypes, different modes of inheritance, dominant negative effects,…”
InfluentialOsteoporosis in Menopause & Beyond
Nasreen, S. Z. A., Shahreen, S., & Parveen, N. T. (2025) · Bangladesh Journal of Obstetrics & Gynaecology · doi:10.3329/bjog.v39i1.82120
BONE STRENGTH AND TECHNIQUES OF ASSESSMENT
Mohanty, S. R. (2023) · doi:10.53555/bf1k0w84
Cheng, X.-Y., Ma, Q., Hou, X., Zhao, C., Yan, Y., Li, J., & Yang, Z. (2025) · British Journal of Radiology · doi:10.1093/bjr/tqaf250
Li, Y., Xie, X., Liu, Y., Gong, Z., Bi, M., & Li, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334913
Bibliometric Analysis Highlights Lesser-Studied Pathways in Bone Remodeling
Davis, E. M., Snyder, J., Mustaklem, B. S., Brown, H. L., Sasse, M. M., Wakefield, C. M., Day, E. A., Battiston, G., Street, S., Broadhurst, G. M., et al. (2025) · Clinical & Translational Metabolism · doi:10.1007/s12018-025-09313-x
“…has significant drawbacks (including counter-indications, short therapeutic windows, and the potential need for a drug holiday) which present considerable challenges for Extended author information available on the last page of the article the long-term management of this chronic condition [7, 8].”
Effects of Hormones and Load on Murine Trabecular and Cortical Bone Turnover
Williamson, A. N. (2024) · Sheffield Hallam University · doi:10.7190/shu-thesis-00727
Ilomäki, J., Wood, S. J., Tan, G. S. Q., Kim, S. J., Leung, M. T. Y., Sing, C., Cheung, C., Lai, E. C., Hsieh, M. H., Ma, T., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07676-x
“Bisphosphonates and denosumab are first-line therapy following hip fracture [2, 3].”
InfluentialZhu, B., Hu, S., Guo, J., Dong, Z., Dong, Y. S., & Li, F. (2023) · Figshare · doi:10.6084/m9.figshare.23258773
Zhu, B., Hu, S., Guo, J., Dong, Z., Dong, Y. S., & Li, F. (2023) · Figshare · doi:10.6084/m9.figshare.23258770
Zhao, D.-C., Lin, X.-Y., Hu, J., Zhou, B., Zhang, Q., Wang, O., Jiang, Y., Weibo, X., 邢小平, & Li, M. (2024) · Figshare · doi:10.6084/m9.figshare.26583432
Rahim, F., Zaki Zadeh, A., Javanmardi, P., Emmanuel Komolafe, T., Khalafi, M., Arjomandi, A., Ghofrani, H. A., & Shirbandi, K. (2024) · Figshare · doi:10.6084/m9.figshare.26603164
Hong, P., Liu, R., Rai, S., Liu, J., Zhou, Y., Zheng, Y., & Li, J. (2024) · Figshare · doi:10.6084/m9.figshare.26569171
Additional file 1 of Association of bone-related biomarkers with femoral neck bone strength
Xia, N., Cai, Y., Wang, W., Bao, C., Li, Y., Xie, Q., Xu, W., & Liu, D. (2022) · Figshare · doi:10.6084/m9.figshare.19808895
Fernandes, C., Campbell-Scherer, D., Lofters, A., Grunfeld, E., Aubrey-Bassler, K., Cheung, H., Latko, K., Tink, W., Lewanczuk, R., Shea-Budgell, M. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25762894
Guo, Y., Liu, Y., Shi, C., Wu, T., Cui, Y., Wang, S., Liu, P., Feng, X., He, Y., & Fu, D. (2021) · Figshare · doi:10.6084/m9.figshare.15253815
Additional file 2 of Association of bone-related biomarkers with femoral neck bone strength
Xia, N., Cai, Y., Wang, W., Bao, C., Li, Y., Xie, Q., Xu, W., & Liu, D. (2022) · Figshare · doi:10.6084/m9.figshare.19808898
Fu, J., Wang, Y., Jiang, Y., Du, J., Xu, J., & Liu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14903723
Zhu, B., Hu, S., Guo, J., Dong, Z., Dong, Y. S., & Li, F. (2023) · Figshare · doi:10.6084/m9.figshare.23258761
Zhao, D.-C., Lin, X.-Y., Hu, J., Zhou, B., Zhang, Q., Wang, O., Jiang, Y., Weibo, X., 邢小平, & Li, M. (2023) · Figshare · doi:10.6084/m9.figshare.26583429
Zhu, B., Hu, S., Guo, J., Dong, Z., Dong, Y. S., & Li, F. (2023) · Figshare · doi:10.6084/m9.figshare.23258767
Xie, Q., Chen, Y., Hu, Y., Zeng, F., Wang, P., Lin, X., Wu, J., Li, J., Zhu, J., Xiang, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20452893
Liu, T., Yao, M., Zhao, Y., Zhao, S., Chen, R., & Yang, F. (2024) · Figshare · doi:10.6084/m9.figshare.26637222
Fernandes, C., Campbell-Scherer, D., Lofters, A., Grunfeld, E., Aubrey-Bassler, K., Cheung, H., Latko, K., Tink, W., Lewanczuk, R., Shea-Budgell, M. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26716525
Fernandes, C., Campbell-Scherer, D., Lofters, A., Grunfeld, E., Aubrey-Bassler, K., Cheung, H., Latko, K., Tink, W., Lewanczuk, R., Shea-Budgell, M. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25763086
Sammenlikning av frakturforebyggende effekt av bisfosfonater ved postmenopausal osteoporose
Fæhn, R. H. (2019) · NORA - Norwegian Open Research Archives
Rheumatoid Arthritis Disease Activity is Associated with Frailty in Veterans
Loecker, C. N. (2024) · DigitalCommons@UNMC
Osteoporosis Implications for the Aging Adult
Alford, G. (2021) · Digital Commons - Otterbein (Otterbein University)
Lee, A. (2023) · MacSphere (McMaster University) · doi:10.71548/9027
Ginásio Clube mega craque : dinâmicas metodológicas
Lopes, A. C. M. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Bhadhuri, A., Sutherland, C. S., Suter-Zimmermann, K., Schwenkglenks, M., Rohrmann, S., Hysaj, O., Tomonaga, Y., Pestoni, G., & Karavasiloglou, N. (2020) · edoc (University of Basel)
Yu, C.-G., Shin, J.-W., Lee, B. H., Kim, H., Moon, S.-H., Park, S.-Y., & Kwon, J.-W. (2025) · Journal of Advanced Spine Surgery · doi:10.63858/jass.15.2.114
Pharmacotherapy of Osteoporosis in Postmenopausal Women narrative review
Chodkowska, E., Schendzielorz, J., Zabrzeński, B., Paks, K., Dyczek, P., Staniszewska, W., Kałuża, K., Lach, S., Mucha, A., & Szeps, A. (2025) · Archiv Euromedica · doi:10.35630/2025/15/iss.6.608
Sundus, H., Aziz, R., Zaidi, S., Khan, H., & Khan, S. A. (2026) · Sport Sciences for Health · doi:10.1007/s11332-025-01619-z
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.